2012 Acquisition Capital Study 
Xconomy
SEPTEMBER 7, 2016
Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. He licensed the drug from San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND ) in March 2012. to $30 apiece.
Tech Zulu Event
FEBRUARY 3, 2014
I’ve been an avid user of Plug.DJ’s music discovery site since early 2012, have discovered a ton of music there (which, by the way, I’m still listening to today) and originally covered their $1.25M in seed-round funding from Javelin Venture Partners. was founded in February 2012 by a team of passionate music fans.
Expert insights. Personalized for you.
40 
Let's personalize your content